EFFECT OF A PLATELET ACTIVATING FACTOR ANTAGONIST (CV6209) ON SHOCK CAUSED BY TEMPORARY HEPATIC INFLOW OCCLUSION

Platelet activating factor (PAF) is a newly discovered inflammatory chemical mediator, which was reported to play a pivotal role in various types of shock. There is also a great possibility that PAF plays an important role in the shock caused by hepatic inflow occlusion. In the present study, the effect of CV6209, a PAF antagonist, on the shock caused by the occlusion was investigated. Intravenous 3μg/kg of PAF caused hypotension in Wistar rats (n=6), and pretreatment with intravenous 3mg/kg of CV6209 significantly (p<0.01) prevented the hypotension (p=6). Forty-five minutes of hepatic inflow occlusion caused hypotension in rats during the occlusion period, and the hypotension continued even after restoration of blood flow in control group (pretreated with saline i.v. only, n=5). In contrast, this hypotension was significantly (p<0.01) reversed in PAF antagonist group (pretreated was 3mg/kg of CV6209 i.v., n=5). In sham-operated rats (n=6), arterial pressure remained unchanged and not hypotensive during the monitoring period. The survival rate of rats 90 minutes after declamp was 30% in control group (n=20), and that was significantly (p<0.05) improved to be 65% in PAF antagonist group (n=20). In conclusion, PAF plays an important role in the shock and death caused by temporary hepatic inflow occlusion, and a PAF antagonist could be a therapeutic drug against temporary hepatic inflow occlusion. © 1990.